• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer

    1/8/26 8:00:00 AM ET
    $ALPS
    Get the next $ALPS alert in real time by email

    KUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ:ALPS) (the "Company" or "Alps Group"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced the appointment of Cheing Lye-Ping (Penny) as Chief Financial Officer (CFO) of the Company, effective January 5, 2026.

    Ms. Cheing will be responsible for leading the development of the financial strategy to support the business, including investment strategies and long-term financial plans. She will also oversee financial budgeting, planning and analysis, audit, and tax compliance for Alps Group and subsidiaries, as well as risk management, accounting, and treasury responsibilities.

    Ms. Cheing has over 30 years of experience in finance and accounting, including senior leadership roles in public-listed and private companies across multiple industries. Prior to joining the Company, from 2014 to 2025, Ms. Cheing served as the CFO of a property development company primarily involved in an integrated mixed-use development project in the city center. From 2009 to 2013, she served as Chief Executive Officer of Premier Asia Capital Sdn. Bhd., where she led the company's investment strategies and managed its investment and joint venture portfolios. From 2003 to 2008, Ms. Cheing headed the corporate affairs department of Equine Capital Berhad, a property development company listed on the Main Market of Bursa Malaysia. In this role, her key responsibilities included financial reporting, corporate finance, corporate governance, risk management, and investor relations. Earlier in her career, from 1995 to 2002, she was with the audit division of Arthur Andersen & Co, where she worked across a range of industries including manufacturing, aviation and logistics, and services. Ms. Cheing holds a Bachelor of Business (Accountancy) from RMIT University, Australia, and a Master of Business Administration from Deakin University, Australia. She is a Chartered Accountant registered with the Malaysian Institute of Accountants and a Fellow of CPA Australia (FCPA).

    Dr. Tham Seng Kong, Chief Executive Officer of Alps Group, stated, "I am excited to welcome Penny to Alps Group's executive leadership team as CFO. She brings extensive experience in finance, accounting and taxation, as well as capital markets insights. We look forward to working with her and our entire team as our business enters a new phase of exciting growth ahead."

    "I'm honored to join Alps Group during such an important time in the Company's evolution," said Ms. Cheing. "The opportunity to contribute to the work already underway is exciting, and the possibilities of what Alps Group can achieve are truly inspiring. I look forward to partnering with not only the leadership team, but the entire company, on their journey."

    About Alps Group

    Alps Group Inc is the parent company of Alps Life Sciences Inc, an integrated biotechnology platform integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally. Alps Group's mission is to promote and create a fair healthcare ecosystem by advancing predictive, preventive, and precision medicine with the aim of improving accessibility and affordability.

    Forward-Looking Statements

    Certain statements in this press release may be considered to contain certain "forward-looking statements" within the meaning of "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "shall," "may," "anticipate," "estimate," "would," "positioned," "future," "forecast," "intend," "plan," "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company management's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

    A further list and description of risks and uncertainties can be found in documents filed with the Securities and Exchange Commission ("SEC") by the Company and other documents that we may file or furnish with the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.

    Investor Relations Contact

    Andrew J. Barwicki

    Tel: 516-662-9461

    Email: [email protected]



    Primary Logo

    Get the next $ALPS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALPS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALPS
    SEC Filings

    View All

    SEC Form 6-K filed by ALPS Group Inc

    6-K - Alps Group Inc (0002025774) (Filer)

    2/4/26 9:14:49 PM ET
    $ALPS

    SEC Form 6-K filed by ALPS Group Inc

    6-K - Alps Group Inc (0002025774) (Filer)

    1/30/26 4:00:28 PM ET
    $ALPS

    SEC Form 424B3 filed by ALPS Group Inc

    424B3 - Alps Group Inc (0002025774) (Filer)

    1/21/26 4:00:52 PM ET
    $ALPS

    $ALPS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy

    KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the "Company" or "Alps Group"), the parent company of Alps Life Sciences Inc. ("Alps Holdco"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a potential expansion of its exosome-related pipeline beyond its previously disclosed CELESOME(+) program. The announcement follows the publication of a preliminary retrospective clinical case series in SAGE Open Medical Case Reports describing nebulized human umbilical cord mesenchymal stem cell ("hUCMSC") derived exosome in patient with asthma and/or chronic obstructive pulmonar

    1/30/26 8:00:00 AM ET
    $ALPS

    Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer

    KUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ:ALPS) (the "Company" or "Alps Group"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced the appointment of Cheing Lye-Ping (Penny) as Chief Financial Officer (CFO) of the Company, effective January 5, 2026. Ms. Cheing will be responsible for leading the development of the financial strategy to support the business, including investment strategies and long-term financial plans. She will also oversee financial budgeting, planning and analysis, audit, and tax compliance for Alps Group and subsidiaries, as well as ris

    1/8/26 8:00:00 AM ET
    $ALPS

    Alpine Announces Status of Sale Process

    Nashville, Tennessee and Vancouver, British Columbia--(Newsfile Corp. - June 21, 2023) - Alpine Summit Energy Partners, Inc. (TSXV:ALPS) (NASDAQ:ALPS) ("Alpine Summit" or the "Company") today announced that its Board of Directors unanimously voted to conclude its previously announced asset sale process, which was being conducted by Stephens Inc. ("Stephens").Beginning on March 8, 2023, Stephens broadly solicited expressions of interest in a sale of various strategic, highly productive assets recently developed and proven by the Company. After considering several bids, the Company's Board of Directors concluded that the bids were not reflective of the value of the underlying assets and it wa

    6/21/23 7:15:00 PM ET
    $ALPS

    $ALPS
    Financials

    Live finance-specific insights

    View All

    Alpine Summit Energy Partners Announces Full Year 2022 Financial and Operating Results

    Nashville, Tennessee and Vancouver, British Columbia--(Newsfile Corp. - March 27, 2023) - Alpine Summit Energy Partners, Inc. (TSXV:ALPS) (NASDAQ:ALPS) ("Alpine Summit" or the "Company") is pleased to announce its financial and operating results for the year ended December 31, 2022. Alpine Summit's audited consolidated financial statements and notes, as well as management's discussion and analysis (the "MD&A") and its Annual Report on Form 10-K for the year ended December 31, 2022 will be available under the Company's issuer profile at "www.sedar.com" and "www.sec.gov/edgar", as well as on the Company's website at "www.alpinesummitenergy.com".Craig Perry, Chief Executive Officer, remarked:

    3/27/23 7:00:00 AM ET
    $ALPS

    Alpine Summit Energy Partners Announces Strategic Review of Assets

    Nashville, Tennessee and Vancouver, British Columbia--(Newsfile Corp. - February 23, 2023) - Alpine Summit Energy Partners, Inc. (TSXV:ALPS) (NASDAQ:ALPS) ("Alpine Summit" or the "Company") today announced that the Board of Directors is commencing a strategic review of its assets. The Company seeks to facilitate a timely and orderly response to unsolicited inquiries by other upstream oil and gas companies who have expressed interest in acquiring various assets of the Company. The goal of the review is to maximize shareholder value and better position the Company for long-term stability and growth.Given the Company's decision to initiate this strategic review, alongside the historic volatil

    2/23/23 8:00:00 AM ET
    $ALPS

    Alpine Summit Energy Partners Announces February 2023 Dividend

    Nashville, Tennessee and Vancouver, British Columbia--(Newsfile Corp. - February 1, 2023) - Alpine Summit Energy Partners, Inc. (TSXV:ALPS) (NASDAQ:ALPS) ("Alpine Summit" or the "Company") is pleased to announce that, in accordance with its current monthly dividend policy, the Board of Directors of the Company has declared a dividend of US$0.0315 per subordinate voting share for the month of February 2023. Simultaneously with declaring the dividend on the subordinate voting shares, the directors also declared a dividend on the Company's multiple voting shares equal to US$3.15 per share and a dividend on the Company's proportionate voting shares equal to US$0.0315 per share.The dividend is pa

    2/1/23 8:00:00 AM ET
    $ALPS

    $ALPS
    Leadership Updates

    Live Leadership Updates

    View All

    Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer

    KUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ:ALPS) (the "Company" or "Alps Group"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced the appointment of Cheing Lye-Ping (Penny) as Chief Financial Officer (CFO) of the Company, effective January 5, 2026. Ms. Cheing will be responsible for leading the development of the financial strategy to support the business, including investment strategies and long-term financial plans. She will also oversee financial budgeting, planning and analysis, audit, and tax compliance for Alps Group and subsidiaries, as well as ris

    1/8/26 8:00:00 AM ET
    $ALPS